ResearcherEhime UniversityNo recent work listed
Takashi Terao
Matched on OpenAlex author ID A5109452734. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper
Papers 6
- Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome for Pancreatic Cancer Due to Early Diagn… First author DOI 10.3390/cancers15030561↗
- Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.8736-21↗
- Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. Co-author DOI 10.1097/md.0000000000027591↗
- ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.3748-19↗
- Early Detection of Pancreatic Cancer in Patients With Chronic Liver Disease Under Hepatocellular Carcinoma Surveillance. First author DOI 10.1016/j.mayocp.2018.12.034↗
- Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients. Co-author DOI 10.1186/s12876-017-0623-8↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mitsuhito Koizumi · 6 shared papers, 2017–2023 · strength 0.59
- Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
- Paper Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in U… DOI 10.2169/internalmedicine.8736-21↗
- Paper Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. DOI 10.1097/md.0000000000027591↗
- Teru Kumagi · 6 shared papers, 2017–2023 · strength 0.59
- Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
- Paper Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in U… DOI 10.2169/internalmedicine.8736-21↗
- Paper Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. DOI 10.1097/md.0000000000027591↗
- Yoichi Hiasa · 6 shared papers, 2017–2023 · strength 0.59
- Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
- Paper Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in U… DOI 10.2169/internalmedicine.8736-21↗
- Paper Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. DOI 10.1097/md.0000000000027591↗
- Nobuaki Azemoto · 5 shared papers, 2017–2023 · strength 0.47
- Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
- Paper Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. DOI 10.1097/md.0000000000027591↗
- Paper ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. DOI 10.2169/internalmedicine.3748-19↗
- Yoshinori Ohno · 5 shared papers, 2017–2023 · strength 0.47
- Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
- Paper Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. DOI 10.1097/md.0000000000027591↗
- Paper ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. DOI 10.2169/internalmedicine.3748-19↗
- Yoshinori Tanaka · 5 shared papers, 2017–2023 · strength 0.47
- Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
- Paper Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. DOI 10.1097/md.0000000000027591↗
- Paper ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. DOI 10.2169/internalmedicine.3748-19↗
- Taira Kuroda · 5 shared papers, 2017–2023 · strength 0.47
- Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
- Paper Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. DOI 10.1097/md.0000000000027591↗
- Paper ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. DOI 10.2169/internalmedicine.3748-19↗
- Ichinosuke Hyodo · 2 shared papers, 2021–2022 · strength 0.23
- Paper Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in U… DOI 10.2169/internalmedicine.8736-21↗
- Paper Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. DOI 10.1097/md.0000000000027591↗
- Hiroshi Ishii · 2 shared papers, 2019–2020 · strength 0.16
- Akinori Asagi · 1 shared paper, 2022 · strength 0.12
- Kaori Hino · 1 shared paper, 2022 · strength 0.12
- Masanori Abe · 1 shared paper, 2020 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.